Quantum Private Wealth LLC Takes $213,000 Position in Bristol-Myers Squibb (NYSE:BMY)

Quantum Private Wealth LLC purchased a new position in shares of Bristol-Myers Squibb (NYSE:BMY) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,124 shares of the biopharmaceutical company’s stock, valued at approximately $213,000.

Other institutional investors have also added to or reduced their stakes in the company. Stiles Financial Services Inc boosted its stake in shares of Bristol-Myers Squibb by 0.9% in the 3rd quarter. Stiles Financial Services Inc now owns 24,747 shares of the biopharmaceutical company’s stock worth $1,280,000 after buying an additional 222 shares during the last quarter. Comprehensive Financial Consultants Institutional Inc. lifted its holdings in Bristol-Myers Squibb by 3.1% during the third quarter. Comprehensive Financial Consultants Institutional Inc. now owns 22,540 shares of the biopharmaceutical company’s stock worth $1,166,000 after acquiring an additional 683 shares during the period. Smith Thornton Advisors LLC purchased a new position in Bristol-Myers Squibb in the third quarter worth $202,000. Verity Asset Management Inc. grew its stake in Bristol-Myers Squibb by 93.9% in the 3rd quarter. Verity Asset Management Inc. now owns 30,342 shares of the biopharmaceutical company’s stock valued at $1,570,000 after purchasing an additional 14,694 shares during the period. Finally, Lewis Asset Management LLC increased its position in shares of Bristol-Myers Squibb by 10.1% during the 3rd quarter. Lewis Asset Management LLC now owns 7,215 shares of the biopharmaceutical company’s stock valued at $373,000 after purchasing an additional 662 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Trading Down 0.5 %

BMY stock opened at $54.46 on Friday. The company has a market capitalization of $110.45 billion, a PE ratio of -15.25, a price-to-earnings-growth ratio of 12.39 and a beta of 0.44. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $56.80. The company’s 50 day moving average price is $51.69 and its two-hundred day moving average price is $46.72. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business’s revenue was up 8.4% compared to the same quarter last year. During the same period last year, the firm posted $2.00 earnings per share. As a group, analysts predict that Bristol-Myers Squibb will post 0.9 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.41%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -66.85%.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Samit Hirawat bought 1,830 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the purchase, the executive vice president now directly owns 62,109 shares in the company, valued at $3,395,499.03. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Barclays boosted their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. Sanford C. Bernstein started coverage on shares of Bristol-Myers Squibb in a research note on Thursday, October 17th. They set a “market perform” rating and a $56.00 price target for the company. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Finally, Citigroup downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $75.00 to $55.00 in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $53.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.